Rescuing a stalled AI program for a $4 billion pharmaceutical manufacturer
A client story in stalled ai program: A global pharmaceutical manufacturer with about $4 billion in annual revenue selected our team to rescue an AI and digital transformation program that had absorbed an estimated $50 million without delivering sustainable returns.
Pharmaceutical – AI consulting

The opportunity
The opportunity
The client’s earlier AI and digital transformation effort, led by a major global consulting firm, spread an estimated $50 million across fragmented initiatives, pilots and platforms. None of them produced a sustainable return on investment, real operational adoption or a meaningful improvement in performance.
In a regulated manufacturing business, that shortfall matters beyond the budget. Quality assurance, regulatory oversight and manufacturing risk management are the areas where AI can make the greatest difference, yet the program had not delivered value there. Confidence in the transformation roadmap needed to be rebuilt.
After a competitive selection process, the client asked WGA Consulting to stabilize the portfolio, rescue the investments worth keeping and reset the strategy around outcomes that can be measured in financial and operational terms.
The solution
How the stalled ai program work ran
Diagnose the existing portfolio: We are conducting a comprehensive diagnostic of the client’s AI portfolio, governance model and technology architecture. The aim is to separate assets worth keeping from initiatives that consume effort without return, and to give leadership a clear picture of where the earlier spending went.
Rescue what works and stop what does not: Viable assets are being carried forward, and low-value initiatives are being retired. The remaining strategy is re-anchored on measurable financial and operational outcomes rather than on activity or experimentation.
Apply AI where quality and compliance risk is highest: A central focus is using AI to automate quality assurance and regulatory compliance activities, identify manufacturing and batch release risks early and flag operational exceptions in real time. These capabilities are designed to strengthen compliance integrity, shorten cycle times and improve first-time-right batch release, while reducing regulatory exposure.
Rebuild the operating model around return on investment: We are introducing a value-driven framework for prioritizing use cases against enterprise risk, quality, supply chain and commercial objectives. Governance is being redesigned with clear ROI accountability and stronger execution discipline. The goal is to move AI from experimentation to scaled operational impact.
The impact
The impact
Stabilize the AI portfolio and rescue viable prior investments: Retire low-value initiatives and re-anchor the strategy on measurable financial and operational outcomes
Automate quality assurance and regulatory compliance activities with AI
Identify manufacturing and batch release risks proactively and flag operational exceptions in real time
Improve first-time-right batch release performance and cycle times while mitigating regulatory exposure
Embed ROI accountability in AI governance and use case prioritization: Why it matters
A stalled AI program is rarely fixed by adding more pilots. The more reliable path is to take honest stock, stop what is not working and point the remaining investment at the processes where performance matters most. In regulated industries, that usually means quality, compliance and manufacturing risk, where both the value of AI and the accountability for it can be measured.
The team
More stalled ai program and client results
Industrial manufacturing
Benchmarking agentic AI readiness across 40+ functions at a $7B manu
Facing something similar?
Tell us where your program stands. A senior consultant, not a sales team, will reply.


